Clinical trial news

The Muscular Dystrophy Association's acronym is shown against a backdrop of polka dots for this MDA Clinical & Scientific Conference illustration.

Evrysdi (risdiplam) may be associated with longer survival and more motor function gains than Spinraza (nusinersen) in children with spinal muscular atrophy (SMA) type 1, according to an indirect comparison of clinical trial data. Sponsored by Roche — which markets Evrysdi — the analysis “leverages the longest…

Evrysdi JEWELFISH update | SMA News Today | MDA doctor with patient illustration

Treatment with Evrysdi (risdiplam) continues to be safe and well tolerated in people with spinal muscular atrophy (SMA) who have previously received other therapies for SMA, according to one-year data from the JEWELFISH clinical trial. Results also suggest that motor function has been stable in JEWELFISH participants after a…

Most children with spinal muscular atrophy (SMA) who were presymptomatic and treated with Spinraza (nusinersen) in the NURTURE clinical trial are hitting major motor milestones within developmentally normal windows, new data show. “It’s only getting better. It’s spectacular,” Thomas Crawford, MD, from Johns Hopkins Medical Institute, said in…

Spinraza use linked to improved arm and hand function | SMA News Today | illustration of doctors using smart tablet

Scholar Rock is on track to initiate a pivotal Phase 3 trial of apitegromab in non-ambulatory patients with type 2 and type 3 spinal muscular atrophy (SMA) by the end of 2021, according to a company press release. The planned randomized, double-blind, and placebo-controlled trial will focus on people…

A half-full prescription medicine bottle bears a label reading 'Clinical Trials.'

Roche and its subsidiary Genentech are launching a Phase 2/3 clinical trial to evaluate the safety and efficacy of GYM329 (RO7204239), an investigational anti-myostatin antibody, in combination with Evrysdi (risdiplam) in children with spinal muscular atrophy (SMA). The MANATEE trial has two parts. In part one, 36…